PE20220942A1 - COMPOSICION DE UN INHIBIDOR DE PI4KIIIalfa DE MOLECULA PEQUENA, METODO DE PREPARACION Y APLICACION DEL MISMO - Google Patents
COMPOSICION DE UN INHIBIDOR DE PI4KIIIalfa DE MOLECULA PEQUENA, METODO DE PREPARACION Y APLICACION DEL MISMOInfo
- Publication number
- PE20220942A1 PE20220942A1 PE2022000005A PE2022000005A PE20220942A1 PE 20220942 A1 PE20220942 A1 PE 20220942A1 PE 2022000005 A PE2022000005 A PE 2022000005A PE 2022000005 A PE2022000005 A PE 2022000005A PE 20220942 A1 PE20220942 A1 PE 20220942A1
- Authority
- PE
- Peru
- Prior art keywords
- present
- amount
- composition
- preparation
- inhibitor
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 150000003384 small molecules Chemical class 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 abstract 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 230000003078 antioxidant effect Effects 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229940114538 phosphatidylinositol 4-kinase inhibitor Drugs 0.000 abstract 1
- 150000003904 phospholipids Chemical class 0.000 abstract 1
- 150000003431 steroids Chemical class 0.000 abstract 1
- 235000015112 vegetable and seed oil Nutrition 0.000 abstract 1
- 239000008158 vegetable oil Substances 0.000 abstract 1
- 229940088594 vitamin Drugs 0.000 abstract 1
- 229930003231 vitamin Natural products 0.000 abstract 1
- 235000013343 vitamin Nutrition 0.000 abstract 1
- 239000011782 vitamin Substances 0.000 abstract 1
- 150000003722 vitamin derivatives Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/285—Arsenic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019094831 | 2019-07-05 | ||
| PCT/CN2020/100377 WO2021004422A1 (zh) | 2019-07-05 | 2020-07-06 | 小分子PI4KIIIα抑制剂组合物、其制备方法及用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20220942A1 true PE20220942A1 (es) | 2022-05-31 |
Family
ID=74115038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022000005A PE20220942A1 (es) | 2019-07-05 | 2020-07-06 | COMPOSICION DE UN INHIBIDOR DE PI4KIIIalfa DE MOLECULA PEQUENA, METODO DE PREPARACION Y APLICACION DEL MISMO |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20230115711A1 (https=) |
| EP (1) | EP3995134A4 (https=) |
| JP (1) | JP2022538505A (https=) |
| KR (1) | KR20220071175A (https=) |
| CN (2) | CN118105372A (https=) |
| AU (1) | AU2020309681A1 (https=) |
| BR (1) | BR112022000155A2 (https=) |
| CA (1) | CA3149104A1 (https=) |
| CO (1) | CO2022001218A2 (https=) |
| IL (1) | IL289586A (https=) |
| MX (1) | MX2022000287A (https=) |
| PE (1) | PE20220942A1 (https=) |
| PH (1) | PH12022550254A1 (https=) |
| TW (1) | TW202126294A (https=) |
| WO (1) | WO2021004422A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114685566A (zh) * | 2020-12-31 | 2022-07-01 | 江苏挪贝肽医药科技有限公司 | 氧化苯砷晶型i、晶型ii和晶型iii及其制备方法 |
| JP2024537837A (ja) * | 2021-09-30 | 2024-10-16 | ヌオ－ベータ・ファーマシューティカル・テクノロジー（シャンハイ）カンパニー・リミテッド | ハロゲン化フェニルアルシンオキシド化合物およびその用途 |
| CN116478954B (zh) * | 2023-02-14 | 2025-06-10 | 中国农业大学 | 水稻基因OsPI4K及其在水稻抗稻瘟病中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002365110A1 (en) * | 2001-07-10 | 2003-07-15 | Massachusetts Institute Of Technology | Small molecule microarrays |
| EP2316943B1 (en) * | 2007-07-05 | 2013-06-19 | Novartis AG | DSRNA for treating viral infection |
| WO2016172952A1 (zh) * | 2015-04-30 | 2016-11-03 | 江苏挪贝肽医药科技有限公司 | PI4KIIIα蛋白及相关的膜蛋白复合体在治疗阿尔茨海默病中的应用 |
| CN112437674A (zh) * | 2018-04-11 | 2021-03-02 | 新墨西哥科技大学研究园公司 | 用于药物递送的脂质前药 |
| BR112022019864A2 (pt) * | 2020-03-31 | 2022-11-16 | Nuo Beta Pharmaceutical Tech Shanghai Co Ltd | Composto de oxofenilarsina deuterada e uso do mesmo |
| JP2024537837A (ja) * | 2021-09-30 | 2024-10-16 | ヌオ－ベータ・ファーマシューティカル・テクノロジー（シャンハイ）カンパニー・リミテッド | ハロゲン化フェニルアルシンオキシド化合物およびその用途 |
-
2020
- 2020-07-03 TW TW109122503A patent/TW202126294A/zh unknown
- 2020-07-06 KR KR1020227003749A patent/KR20220071175A/ko not_active Ceased
- 2020-07-06 CA CA3149104A patent/CA3149104A1/en active Pending
- 2020-07-06 BR BR112022000155A patent/BR112022000155A2/pt not_active Application Discontinuation
- 2020-07-06 JP JP2022526849A patent/JP2022538505A/ja active Pending
- 2020-07-06 PH PH1/2022/550254A patent/PH12022550254A1/en unknown
- 2020-07-06 CN CN202311755839.1A patent/CN118105372A/zh active Pending
- 2020-07-06 AU AU2020309681A patent/AU2020309681A1/en not_active Abandoned
- 2020-07-06 EP EP20836327.5A patent/EP3995134A4/en active Pending
- 2020-07-06 CN CN202080049288.5A patent/CN114555056B/zh active Active
- 2020-07-06 US US17/624,850 patent/US20230115711A1/en active Pending
- 2020-07-06 WO PCT/CN2020/100377 patent/WO2021004422A1/zh not_active Ceased
- 2020-07-06 MX MX2022000287A patent/MX2022000287A/es unknown
- 2020-07-06 PE PE2022000005A patent/PE20220942A1/es unknown
-
2022
- 2022-01-03 IL IL289586A patent/IL289586A/en unknown
- 2022-02-07 CO CONC2022/0001218A patent/CO2022001218A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020309681A1 (en) | 2022-02-24 |
| KR20220071175A (ko) | 2022-05-31 |
| CO2022001218A2 (es) | 2022-05-20 |
| IL289586A (en) | 2022-03-01 |
| WO2021004422A1 (zh) | 2021-01-14 |
| CA3149104A1 (en) | 2021-01-14 |
| JP2022538505A (ja) | 2022-09-02 |
| EP3995134A4 (en) | 2023-07-12 |
| MX2022000287A (es) | 2022-06-16 |
| US20230115711A1 (en) | 2023-04-13 |
| EP3995134A1 (en) | 2022-05-11 |
| CN118105372A (zh) | 2024-05-31 |
| CN114555056B (zh) | 2024-01-05 |
| TW202126294A (zh) | 2021-07-16 |
| PH12022550254A1 (en) | 2023-06-26 |
| CN114555056A (zh) | 2022-05-27 |
| BR112022000155A2 (pt) | 2022-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20220942A1 (es) | COMPOSICION DE UN INHIBIDOR DE PI4KIIIalfa DE MOLECULA PEQUENA, METODO DE PREPARACION Y APLICACION DEL MISMO | |
| BR112022024943A2 (pt) | Composição oral efervescente compreendendo um ingrediente ativo | |
| PY2085961A (es) | Formulaciones de cannabinoides orales | |
| MA40111A1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
| BR112023021160A2 (pt) | Lipídeos ionizáveis e composições para liberação em ácido nucleico | |
| AR112536A1 (es) | Métodos para reducir la formación de partículas y composiciones elaboradas a través de los mismos | |
| AR108074A1 (es) | Composiciones de hormona esteroide en aceites de cadena media | |
| PE20050138A1 (es) | Aceites de pescado con un perfil alterado de acidos grasos, un metodo para producir esos aceites y uso de ellos | |
| ECSP066701A (es) | Derivados de sulfonamida para el tratamiento de enfermedades | |
| BR112013020167A2 (pt) | melhoradores de permeação para formulações tópicas | |
| BRPI0916936B8 (pt) | composições farmacêuticas, uso de clevidipina e método de reduzir impurezas. | |
| CL2022002564A1 (es) | Combinaciones de brimonidina de dosis baja y usos de las mismas. (solicitud divisional de 201903572) | |
| BR0013385A (pt) | Composições farmacêuticas para administração oral e tópica | |
| MX2021015311A (es) | Formulas parenterales de lisofosfatidilcolina tales como lpc-dha, lpc-epa y sus usos en terapia. | |
| MX2021014371A (es) | Composiciones que comprenden acidos grasos cetilados y uso de las mismas en el tratamiento de la artritis y de afecciones inflamatorias de las articulaciones. | |
| BR112015028696A2 (pt) | composições de óleo estruturadas | |
| UY40282A (es) | Compuestos amido-heteroaromáticos | |
| MX2021014297A (es) | Procedimiento para preparar una composicion que comprende acidos grasos cetilados. | |
| PE20211198A1 (es) | Metodos y formulaciones para tratar nauseas y vomitos inducidos por quimioterapia | |
| UY33404A (es) | Composiciones farmacéuticas topicas | |
| MX2022006502A (es) | Composiciones farmaceuticas. | |
| AR128535A1 (es) | Composición para el cuidado del cabello | |
| PE20221446A1 (es) | Nuevas formulaciones de comprimido de fosfomicina | |
| CN107865784A (zh) | 一种基于协同美白作用的纳米级胶束爽肤水 | |
| WO2019004968A3 (en) | USE OF A VEGETABLE FORMULATION CONTAINING GRANADIAN PINE OIL AS AN AGENT ENHANCING THE IMMUNE SYSTEM DUE TO ITS ANTIOXIDANT FUNCTION |